Fluidigm Corporation (NASDAQ:FLDM) Director Samuel D. Colella bought 35,895 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were purchased at an average cost of $2.77 per share, for a total transaction of $99,429.15. Following the transaction, the director now owns 45,197 shares in the company, valued at $125,195.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Fluidigm Corporation (NASDAQ:FLDM) traded up 14.02% during midday trading on Tuesday, hitting $3.09. 873,968 shares of the company were exchanged. The stock’s market capitalization is $90.52 million. The stock has a 50 day moving average of $3.84 and a 200-day moving average of $5.08. Fluidigm Corporation has a 1-year low of $2.52 and a 1-year high of $9.65.

Fluidigm Corporation (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.02. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 104.38%. The firm’s revenue for the quarter was down 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. Equities analysts expect that Fluidigm Corporation will post ($2.19) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Fluidigm Corporation (NASDAQ:FLDM) Director Buys 35,895 Shares of Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/insider-buying-fluidigm-corporation-nasdaqfldm-director-buys-35895-shares-of-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of FLDM. American International Group Inc. increased its position in Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock valued at $102,000 after buying an additional 1,187 shares during the last quarter. AQR Capital Management LLC acquired a new position in Fluidigm Corporation during the fourth quarter valued at $119,000. Stoneridge Investment Partners LLC increased its position in Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock valued at $144,000 after buying an additional 1,013 shares during the last quarter. Wells Fargo & Company MN increased its position in Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock valued at $146,000 after buying an additional 3,327 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock valued at $151,000 after buying an additional 632 shares during the last quarter. Institutional investors own 91.66% of the company’s stock.

Several equities analysts have commented on FLDM shares. Zacks Investment Research cut shares of Fluidigm Corporation from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. ValuEngine cut shares of Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.